Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F DiPersio

Showing results (51-60 of 342) with videos related to

Pageof 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell TransplantationJoseph C Rimando, Matthew J Christopher, Michael P Rettig, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 31, 2017
OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral bloodKarl W Staser, William Eades, Jaebok Choi, et al.
Leukemia & Lymphoma|January 20, 2009
Dasatinib in relapsed or plateau-phase multiple myelomaTanya M Wildes, Elizabeth Procknow, Feng Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaAmanda F Cashen, Gary J Schiller, Margaret R O'Donnell, et al.
Blood Advances|July 5, 2024
Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantationStephen P Persaud, Aditya R Yelamali, Julie K Ritchey, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|May 30, 2024
Integration of Clinical Trial Development in Hematology-Oncology Fellowship TrainingChristine Auberle, Ningying Wu, John F Dipersio, et al.
Haematologica|October 18, 2006
The activity and toxicity of low dose clofarabine against relapsed or refractory myelomaGeoffrey L Uy, Michael H Tomasson, Alisa Ruddell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 2010
Relevance and clinical implications of tumor cell mobilization in the autologous transplant settingJohn F DiPersio, Anthony D Ho, Jessie Hanrahan, et al.
Future Oncology (London, England)|September 10, 2019
GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myelomaZachary D Crees, Keith Stockerl-Goldstein, Abi Vainstein, et al.
Plos One|November 20, 2018
Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantationBader Alahmari, Matthew Cooper, Edward Ziga, et al.
Pageof 35

Showing results (51-60 of 342) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell TransplantationJoseph C Rimando, Matthew J Christopher, Michael P Rettig, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 31, 2017
OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral bloodKarl W Staser, William Eades, Jaebok Choi, et al.
Leukemia & Lymphoma|January 20, 2009
Dasatinib in relapsed or plateau-phase multiple myelomaTanya M Wildes, Elizabeth Procknow, Feng Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaAmanda F Cashen, Gary J Schiller, Margaret R O'Donnell, et al.
Blood Advances|July 5, 2024
Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantationStephen P Persaud, Aditya R Yelamali, Julie K Ritchey, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|May 30, 2024
Integration of Clinical Trial Development in Hematology-Oncology Fellowship TrainingChristine Auberle, Ningying Wu, John F Dipersio, et al.
Haematologica|October 18, 2006
The activity and toxicity of low dose clofarabine against relapsed or refractory myelomaGeoffrey L Uy, Michael H Tomasson, Alisa Ruddell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 2010
Relevance and clinical implications of tumor cell mobilization in the autologous transplant settingJohn F DiPersio, Anthony D Ho, Jessie Hanrahan, et al.
Future Oncology (London, England)|September 10, 2019
GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myelomaZachary D Crees, Keith Stockerl-Goldstein, Abi Vainstein, et al.
Plos One|November 20, 2018
Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantationBader Alahmari, Matthew Cooper, Edward Ziga, et al.
Pageof 35